ANTX:NSD-AN2 Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 11.20

Change

0.00 (0.00)%

Market Cap

USD 0.22B

Volume

0.06M

Avg Analyst Target

USD 22.00 (+96.43%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ANTX Stock Forecast & Price:
Based on the AN2 Therapeutics Inc stock forecasts from 1 analysts, the average analyst target price for AN2 Therapeutics Inc is USD 22.00 over the next 12 months. AN2 Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of AN2 Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, AN2 Therapeutics Inc’s stock price was USD 11.20. AN2 Therapeutics Inc’s stock price has changed by +26.84% over the past week, -33.92% over the past month and 0% over the last year.

About AN2 Therapeutics Inc (ANTX:NSD)

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

N/A

USD76.01B 13.77 10.63
VRTX Vertex Pharmaceuticals Inc

N/A

USD72.69B 23.48 15.78
MRNA Moderna Inc

N/A

USD48.37B 3.93 2.93
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

USD31.55B 2.99 1.31
RPRX Royalty Pharma Plc

N/A

USD27.26B 39.54 19.50
SGEN Seagen Inc

N/A

USD25.67B 55.02 -36.47
ALNY Alnylam Pharmaceuticals Inc

N/A

USD24.33B N/A -33.90
GMAB Genmab AS

N/A

USD22.20B 42.20 3.93
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ANTX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -78.26% 40% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -78.26% 40% F 13% F
Average Annual (5 Year Horizon)  
Capital Gain 1.36% 64% D 56% F
Dividend Return 1.01% 36% F 29% F
Total Return 2.36% 65% D 54% F
Risk Return Profile  
Volatility (Standard Deviation) 4.33% 99% A+ 88% B+
Risk Adjusted Return 54.53% 94% A 87% B+
Market Capitalization 0.22B 60% D- 45% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 3.96 56% F 87% B+
Price/Book Ratio 1.88 50% F 42% F
Price / Cash Flow Ratio -10.61 80% B- 70% C-
EV/EBITDA -3.19 74% C 70% C-
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 63.71% 93% A 94% A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 2.63 59% F 50% F
Short Percent 1.32% 70% C- 62% D-
Beta 0.73 71% C- 72% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector